3-(Hydrazinecarbonyl)pyrrolidine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(Hydrazinecarbonyl)pyrrolidine-1-carboxylic acid
• 英文别名: 3-(hydrazinecarbonyl)pyrrolidine-1-carboxylic acid
• 化学式: C₆H₁₁N₃O₃
• 分子量: 173.17
• InChiKey: AZDRDYAPQAJLAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  95.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND &bgr;-LACTAMASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS BICYCLIQUES ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS ET INHIBITEURS DE &Bgr;-LACTAMASE
  申请人：NAEJA PHARMACEUTICAL INC

  公开号：WO2014091268A1

  公开（公告）日：2014-06-19

  A compound of formula (I), wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  式（I）的化合物，其中：M为氢或药用可接受的盐形成阳离子；Y为OR1或NR2R3，R1、R2、R3和M如本文所定义。此外，治疗细菌感染的方法，制药组合物，分子复合物和制备化合物的方法。
• [EN] 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE<br/>[FR] DÉRIVÉS D'AMINO TRIAZOLO QUINAZOLINE À SUBSTITUTION EN POSITIONS 7, 8 ET 10 UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2020112706A1

  公开（公告）日：2020-06-04

  In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  在其多种实施方式中，本发明提供了某些7-、8-和10-取代氨基三唑喹唑啉衍生物的化合物（I）的制备方法和用途，或其药学上可接受的盐，其中环A、R1、R2和R4如本文所定义，包括一种或多种这样的化合物的药物组合物（单独使用和与一种或多种其他治疗剂联合使用），以及其制备和用途的方法，单独使用和与其他治疗剂联合使用，作为A2a和/或A2b受体的拮抗剂，并且它们在治疗由腺苷A2a受体和/或腺苷A2b受体至少部分介导的各种疾病、症状或紊乱中的用途。
• NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND -LACTAMASE INHIBITORS
  申请人：Fedora Pharmaceuticals Inc.

  公开号：EP2931723A1

  公开（公告）日：2015-10-21
• 7-, 8-, AND 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3887377A1

  公开（公告）日：2021-10-06
• 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20220220117A1

  公开（公告）日：2022-07-14

  In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R 1 and R 2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.